ETF Holdings Breakdown of AKRO

AKRO institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	40,498	USD 1,933,375
2025-09-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	6,415	USD 306,252
2025-09-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	45,359	USD 2,165,439
2025-09-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	45,359	USD 2,165,439
2025-09-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	306	USD 14,608 3.2%
Total =		137,937	USD 6,585,113

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with AKRO

Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $81.57 Average Target Price from Analysts

Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has received a consensus rating of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on the stock in […] - 2025-09-05 02:52:56

Akero Therapeutics (NASDAQ:AKRO) Research Coverage Started at TD Cowen

TD Cowen assumed coverage on shares of Akero Therapeutics (NASDAQ:AKRO – Free Report) in a research note published on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $76.00 target price on the stock. AKRO has been the subject of several other research reports. Citigroup dropped their price target on shares of […] - 2025-08-07 02:54:52

Universal Beteiligungs und Servicegesellschaft mbH Invests $463,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,436 shares of the company’s stock, valued at approximately $463,000. A number of other […] - 2025-08-04 05:14:50

KLP Kapitalforvaltning AS Cuts Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)

KLP Kapitalforvaltning AS decreased its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 12.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,600 shares of the company’s stock after selling 1,400 shares during the […] - 2025-07-31 05:14:49

Jennison Associates LLC Purchases Shares of 13,178 Akero Therapeutics, Inc. (NASDAQ:AKRO)

Jennison Associates LLC bought a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 13,178 shares of the company’s stock, valued at approximately $533,000. Several other institutional investors and hedge funds have also […] - 2025-07-23 06:20:51

Akero Therapeutics, Inc. (NASDAQ:AKRO) Position Increased by Bank of New York Mellon Corp

Bank of New York Mellon Corp raised its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 6.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,665 shares of the company’s stock after acquiring an additional 12,235 shares […] - 2025-07-22 08:19:03

Bank of New York Mellon Corp Acquires 12,235 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

Bank of New York Mellon Corp raised its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 6.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 212,665 shares of the company’s stock after buying an additional 12,235 shares during the quarter. Bank […] - 2025-07-22 07:24:51

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells $1,534,800.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) CEO Andrew Cheng sold 30,000 shares of the company’s stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $51.16, for a total value of $1,534,800.00. Following the sale, the chief executive officer directly owned 520,757 shares of the company’s […] - 2025-07-14 06:16:53

Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Consensus Recommendation of “Buy” by Brokerages

Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has received a consensus recommendation of “Buy” from the six research firms that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last […] - 2025-07-14 05:38:47

Mirae Asset Global Investments Co. Ltd. Purchases 338 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

Mirae Asset Global Investments Co. Ltd. grew its position in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 14.5% during the first quarter, HoldingsChannel reports. The firm owned 2,664 shares of the company’s stock after buying an additional 338 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Akero Therapeutics were worth […] - 2025-07-07 04:41:41

Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $82.50 Average Target Price from Analysts

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have been assigned a consensus rating of “Buy” from the six analysts that are covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the […] - 2025-06-24 03:11:00

Millennium Management LLC Sells 57,892 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

Millennium Management LLC decreased its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 77.6% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 16,736 shares of the company’s stock after selling 57,892 shares during the period. Millennium Management LLC’s holdings in Akero Therapeutics […] - 2025-06-10 05:18:54

Akero Therapeutics Sees Unusually High Options Volume (NASDAQ:AKRO)

Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) was the target of some unusual options trading on Monday. Stock traders bought 3,105 call options on the company. This represents an increase of approximately 106% compared to the average volume of 1,508 call options. Insider Activity In other news, insider Timothy Rolph sold 12,500 shares of […] - 2025-06-10 02:00:51

Akero Therapeutics (NASDAQ:AKRO) Given New $64.00 Price Target at Bank of America

Akero Therapeutics (NASDAQ:AKRO – Free Report) had its target price raised by Bank of America from $63.00 to $64.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. Other research analysts also recently issued research reports about the company. Citigroup reduced their price target on Akero Therapeutics […] - 2025-05-28 02:44:51

ProShare Advisors LLC Grows Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)

ProShare Advisors LLC boosted its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 32.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 22,398 shares of the company’s stock after acquiring an additional 5,477 shares during the period. ProShare Advisors LLC’s holdings in Akero Therapeutics were worth $623,000 as of […] - 2025-05-26 05:16:50

Akero Therapeutics (NASDAQ:AKRO) Price Target Cut to $78.00 by Analysts at Citigroup

Akero Therapeutics (NASDAQ:AKRO – Free Report) had its price objective decreased by Citigroup from $80.00 to $78.00 in a research note issued to investors on Tuesday,Benzinga reports. Citigroup currently has a buy rating on the stock. Several other analysts have also weighed in on AKRO. HC Wainwright raised their price objective on shares of Akero […] - 2025-05-14 04:58:49

Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $76.29 Average Price Target from Analysts

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have earned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued ratings on the stock […] - 2025-05-05 04:28:56

Sterling Capital Management LLC Boosts Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Sterling Capital Management LLC lifted its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 764.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,789 shares of the company’s stock after purchasing an additional 1,582 shares during the period. Sterling Capital Management LLC’s holdings in Akero […] - 2025-04-24 05:56:54

Vanguard Group Inc. Has $103.06 Million Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Vanguard Group Inc. raised its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 0.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 3,704,411 shares of the company’s stock after purchasing an additional 27,830 shares during the period. Vanguard Group Inc. owned approximately […] - 2025-04-10 04:38:50

KLP Kapitalforvaltning AS Invests $306,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO)

KLP Kapitalforvaltning AS acquired a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 11,000 shares of the company’s stock, valued at approximately $306,000. A number of other hedge funds and other institutional investors have also recently bought and sold shares of AKRO. Handelsbanken […] - 2025-04-07 05:06:49

Akero Therapeutics (NASDAQ:AKRO) and Rezolute (NASDAQ:RZLT) Head to Head Comparison

Rezolute (NASDAQ:RZLT – Get Free Report) and Akero Therapeutics (NASDAQ:AKRO – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Analyst Ratings This is a breakdown of recent ratings […] - 2025-03-26 04:10:42

Y Intercept Hong Kong Ltd Lowers Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Y Intercept Hong Kong Ltd lessened its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 47.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 8,950 shares of the company’s stock after selling 7,966 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Akero Therapeutics were worth $249,000 at […] - 2025-03-05 07:07:16

Akero Therapeutics (NASDAQ:AKRO) Price Target Raised to $75.00

Akero Therapeutics (NASDAQ:AKRO – Free Report) had its target price boosted by HC Wainwright from $72.00 to $75.00 in a report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock. AKRO has been the topic of several other reports. Canaccord Genuity Group lifted their price target on shares of Akero […] - 2025-03-04 04:50:49

Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock Position Decreased by Global Retirement Partners LLC

Global Retirement Partners LLC lessened its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 13.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,917 shares of the company’s stock after selling 740 shares during the period. Global […] - 2025-02-27 06:52:59

Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $75.86 Consensus Target Price from Analysts

Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has been given an average recommendation of “Buy” by the nine analysts that are covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have covered the stock in the last […] - 2025-02-19 05:06:50

Back to Listing

Disclaimer